Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release oral tablet for oral use. It is employed to prevent acute rejection in patients who have undergone renal, heart, or liver transplantation by inhibiting lymphocyte proliferation.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to strict quality standards and provides reliable global distribution for this essential transplant medication.

Myfortic (mycophenolate sodium) is used in transplantation medicine to suppress immune‑mediated graft rejection. - Renal transplantation: helps prevent acute rejection of the transplanted kidney. - Heart transplantation: helps prevent acute rejection of the transplanted heart. - Liver transplantation: helps prevent acute rejection of the transplanted liver.

Myfortic may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Severe infection: sepsis or opportunistic infections. - Malignancy: increased risk of lymphoproliferative disorders or skin cancers. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Reproductive toxicity: teratogenic effects and possible infertility.

When prescribing Myfortic, clinicians should consider several safety precautions to minimize risks. - Monitor blood counts: regular CBC testing to detect anemia, leukopenia, or thrombocytopenia. - Assess renal function: adjust therapy if creatinine clearance declines. - Screen for infections: evaluate for latent viral infections such as CMV or EBV before initiation. - Counsel on pregnancy risk: drug is classified as pregnancy category D; avoid use in pregnant women unless benefits outweigh risks. - Review concomitant immunosuppressants: avoid excessive immunosuppression that could increase infection risk. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Myfortic can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of mycophenolate. - Cyclosporine: increases mycophenolate exposure, raising risk of toxicity. - Tacrolimus: may require dose adjustment due to additive immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: combined use can enhance bone marrow suppression. - Live vaccines: increased risk of infection; avoid administration while on therapy. - Cholesterol‑lowering agents (e.g., statins): monitor for mycophenolate‑related liver enzyme changes.